A Trial Use of Prophylactic Low-Dose Lipo PGE1 (Eglandin) for the Prevention of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation in Children with Hematologic Malignancies.
- Author:
Bin CHO
1
;
In Kyung SUNG
;
Dong Wook KIM
;
Hyun Jung LEE
;
Soh Yeon KIM
;
Nak Gyun CHUNG
;
Chun Choo KIM
;
Hack Ki KIM
Author Information
1. Department of Pediatrics, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Hepatic veno-occlusive disease;
VOD;
Prostaglandine E1;
Lipo Prostaglandine E1;
Eglandin;
Stem cell transplantation
- MeSH:
Alprostadil*;
Bone Marrow;
Child;
Hematologic Neoplasms*;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Hepatic Veno-Occlusive Disease*;
Humans;
Incidence;
Infusions, Intravenous;
Siblings;
Stem Cell Transplantation;
Vasodilation
- From:Korean Journal of Pediatric Hematology-Oncology
2000;7(2):242-248
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: In this study we tested the hypothesis that vasodilatation and antithrombogenic effect in damaged vessels using low-dose Lipo PGE1 might result in increased sinusoidal blood flow and in decreased obstruction and minimize the incidence or severity of hepatic veno-occlusive disease (VOD). METHPDS: Children underwent hematopoietic stem cell transplantation for hematologic malignancies were enrolled in this study. Lipo PGE1 was begun one day prior to the start of conditioning to day 30 after stem cell transplantation in continuous intravenous infusion at a dose of 1 mug/kg/day (0.042 mug/ kg/hr). We evaluate the incidence and severity of hepatic VOD and the toxicity of Lipo PGE1. RESULTS: From November 1999 to Jun 2000, 20 patients (M:F=15:5, median age 5 years) underwent hematopoietic stem cell (5 matched sibling bone marrow, 4 autologous bone marrow, 8 unrelated bone marrow, 3 unrelated cord blood) transplantation for hematologic malignancies (9 ALL, 8 AML, 3 CML) were enrolled in this study. There was no occurrence of VOD within 30 day of transplant. Only one out of 20 patients was diagnosed as delayed VOD, easily controlled moderate form, on post-transplant day 58. There was no toxicity attributed to Lipo PGE1. CONCLUSION: This study suggests that prophylactic low-dose Lipo PGE1 treatment may decrease the incidence of VOD in patients treated for hematologic malignancies by hematopoietic stem cell transplantation.
